



National Institutes of Health
Office of Research on Women's Health



Elise C. Kohn, M.D., FAAAS (she/her)

Head, Gynecologic Cancer Therapeutics, Cancer Therapy Evaluation Program, National Cancer Institute

Dr. Elise Kohn reviews, coordinates, and oversees development and execution to promote scientifically driven and practice-changing trials in gynecologic cancers and neuroendocrine cancers. She also provides disease expertise for early-phase trials in these cancers. Dr. Kohn also applies her prior experience as an intramural laboratory principal investigator to the oversight and guidance of the National Clinical Trials Network's (NCTN) Core Correlative Sciences Committee (CCSC). The CCSC reviews proposals for correlative science to be applied to biospecimens from NCTN clinical trials after protocol-specified integrated endpoints are completed.



Dr. Kohn trained at the University of Michigan and received medical oncology training at the National Cancer Institute (NCI). Dr. Kohn spent over two decades overseeing a laboratory and clinical program in the NCI Intramural Research Program focused on molecular signal transduction targets in invasion, metastasis, and angiogenesis and on proteomic applications applied toward ovarian cancer. Her clinical program focused on application of novel agents and translational opportunities to women's cancers, especially ovarian cancer, via Phase I and II studies. She is now head of Gynecologic Cancer Therapeutics in NCI's Cancer Therapy Evaluation Program, where she coordinates development and execution of the advanced Phase II and III gynecologic cancer clinical trials portfolio. Dr. Kohn also oversees and guides studies in neuroendocrine cancers.